Clinical observation of albumin-bound paclitaxel plus S-1 in patients with advanced pancreatic cancer after the failure of gemcitabine

彭小波; 颜芳

doi:10.3969/j.issn.1007-3969.2015.01.011

您当前的位置：

首页 >

文章列表页 >

Clinical observation of albumin-bound paclitaxel plus S-1 in patients with advanced pancreatic cancer after the failure of gemcitabine

更新时间：2025-12-31

- Clinical observation of albumin-bound paclitaxel plus S-1 in patients with advanced pancreatic cancer after the failure of gemcitabine
- China Oncology Vol. 25, Issue 1, Pages: 63-66(2015)
- 作者机构：
  
  第二军医大学附属长海医院肿瘤科,上海,200433
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.01.011
  CLC：
- Published Online：08 May 2015，
  
  Published：08 May 2015
- 稿件说明：
移动端阅览
彭小波,颜芳,王斌等. 白蛋白结合型紫杉醇联合替吉奥治疗吉西他滨治疗失败进展期胰腺癌的临床观察[J]. 中国癌症杂志, 2015, 25(1): 63-66.

彭小波, 颜芳. Clinical observation of albumin-bound paclitaxel plus S-1 in patients with advanced pancreatic cancer after the failure of gemcitabine[J]. China Oncology, 2015, 25(1): 63-66.
彭小波,颜芳,王斌等. 白蛋白结合型紫杉醇联合替吉奥治疗吉西他滨治疗失败进展期胰腺癌的临床观察[J]. 中国癌症杂志, 2015, 25(1): 63-66. DOI： 10.3969/j.issn.1007-3969.2015.01.011.

彭小波, 颜芳. Clinical observation of albumin-bound paclitaxel plus S-1 in patients with advanced pancreatic cancer after the failure of gemcitabine[J]. China Oncology, 2015, 25(1): 63-66. DOI： 10.3969/j.issn.1007-3969.2015.01.011.

摘要

背景与目的：化疗是晚期胰腺癌患者的主要治疗手段，但目前尚没有二线治疗晚期胰腺癌的标准方案。本研究旨在评估白蛋白结合型紫杉醇联合替吉奥二线治疗吉西他滨治疗失败进展期胰腺癌的近期疗效和安全性。方法：19例接受吉西他滨一线治疗失败的晚期胰腺癌患者，应用白蛋白结合型紫杉醇联合替吉奥二线治疗。白蛋白结合型紫杉醇用药剂量125 mg/m

，静脉滴注30 min，第1、8天给药；替吉奥胶囊40 mg，口服，每日2次，第1～14天；每3周重复。结果：所有患者均可评价疗效，其中完全缓解(complete response，CR)1例，部分缓解(partial response，PR)4例，疾病稳定(stable disease，SD)9例，客观有效率(objective response rate，ORR)为26.3%，疾病控制率(disease control rate，DCR)为73.7%，中位无进展生存期(progression free survival，PFS)为5.2个月。主要不良反应包括血液学毒性、肌肉关节酸痛、消化道反应、感觉神经病变、疲乏和脱发等。结论：白蛋白结合型紫杉醇联合替吉奥方案二线治疗既往吉西他滨治疗失败进展期胰腺癌疗效确切，且不良反应可以耐受。

Abstract

Background and purpose: Pancreatic cancer is often diagnosed at advanced stage

therefore

chemotherapy remains the cornstone of treatment for advanced pancreatic cancer. However

no standard regimen has been established as second-line therapy for advanced pancreatic cancer. The purpose of the study was to evaluate the efficacy and safety of albumin-bound paclitaxel plus S-1 for the treatment of advanced pancreatic cancer patients in second-line setting after the failure of gemcitabine treatment. Methods: Clinical outcomes of 19 patients with advanced pancreatic cancer were analyzed. These patients received album

in-bound paclitaxel plus S-1 as second-line therapy after the failure of gemcitabine treatment. Albumin-bound paclitaxel was administered at a dose of 125 mg/m2 over 30 minutes on day 1 and 8 of a 21-day cycle. From d1-14

all patients received oral S-1 40 mg/m

twice daily. Results: All patients were available for evaluation. Of the 19 patients

1 case got complete response (CR)

4 cases had partial response (PR) and 9 cases had stable disease (SD). The objective response rate (ORR) was 26.3%

the disease control rate (DCR) was 73.7% and the median progression free survival (PFS) was 5.2 months. The main toxicities include hematological toxicity

myodynia

gastrointestinal reactions

sensory neuropathy

fatigue and alopecia. Conclusion: The combination of albumin-bound paclitaxel and S-1 is effective and tolerated in the treatment of advanced pancreatic cancer patients who resistant to gemcitabine.

关键词

Keywords

references

Views

4844

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A research on the mechanism of SERPINA3 promoting malignant progression and gemcitabine resistance of pancreatic cancer by inhibiting ferroptosis

An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer

Research on uPAR promoting proliferation, migration, and chemoresistance of pancreatic cancer by inhibiting autophagy via MAPK signaling

The effects of secretory clusterin on oxidative damage in MIA PaCa-2 cells treated by gemcitabine and preliminary mechanism of resistance to gemcitabine

BRD4 scilencing plus gemcitabine may be a novel therapy for triple-negative breast cancer

Related Author

Jingbiao HUANG

Yuan HE

Juncheng GUO

Zhibin YE

Xiaohu WANG

Haonan LI

Jiaqiang REN

Shuai WU

Related Institution

Department of Gastrointestial Surgery, Heping Hospital Affiliated to Changzhi Medical College

The First Clinical College of Changzhi Medical College

Department of Gastrointestial Surgery, Hebei General Hospital

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiao Tong University

School of Public Health, Xi’an Jiao Tong University Health Science Center

AI问答

⁰